US SEC Trading Suspension Halt Orders — May 12, 2026

Failed Nasdaq Rule 5620(a) annual meeting within 1 year of FYE April 30, 2026; compliance plan due 45 days from May 6 (~June 20); no insider buys or positive guidance

Nasdaq notice for unspecified continued listing failure (Item 3.01); references risks in FY 2025 10-K; high materiality 10/10 with no remediation timeline

Dual non-compliance with Rule 5550(a)(2) bid <$1 for 10 consec days as of May 4, 2026, and Rule 5250(c)(1) late 10-K; ineligible for plan review

Potential 180-day extension from FYE April 30 (~Oct 27, 2026) if plan accepted, but governance lapse signals weak board control vs peers

Forward-looking intent to regain compliance but warns of material risks differing from plans; no period trends or insider data to counter negative sentiment

Trading suspension at open May 13, 2026, Form 25-NSE delisting, shift to OTC same ticker; appeal planned by May 13 but no success assurance

2/3 notices on May 6, 2026, indicating clustered Nasdaq enforcement; absent capital allocation (dividends/buybacks) suggests no shareholder protections

Press release May 12 (Ex 99.1) discloses ineligibility for compliance due to late 10-K under Rule 5810(c); relative worst vs peers

Common stock specifically flagged; no operational metrics or ratios provided, amplifying uncertainty vs Maison's clearer timeline

Plans annual meeting 'as soon as practicable' post-plan submission, but 9/10 materiality trails peers' 10/10

Annual meeting not held within 1 year FYE April 30, 2026, violating Rule 5620(a); 45-day plan deadline ~June 20 heightens delisting risk

Unspecified Nasdaq failure with 10/10 materiality; forward risks tied to 2025 10-K suggest broader operational woes

Bid <$1 for 10 days to May 4 + late 10-K; immediate suspension May 13, delisting via Form 25-NSE

Plans Hearing Panel appeal by May 13 but ineligible for plan review per Rule 5810(c); no assurance of reinstatement

3/3 negative sentiment, all May 2026 notices; potential portfolio contagion for small-cap holders amid no positive insider activity

Actual results may 'differ materially' from compliance intent; absent metrics imply deteriorating trends vs prior periods

180-day max from April 30 (~Oct 27) conditional on Nasdaq acceptance; governance lag vs peers signals control issues

OTC shift post-May 13 suspension erodes trading volume/access; no capital allocation data for buffers

Imminent halt May 13 + OTC delisting offers short alpha pre-event; bid <$1 confirms downside momentum

Monitor plan submission ~June 20 for potential extension to Oct 2026; relative better timeline vs BKYI for turnaround bet

Unspecified deficiency may reveal fixable issue; watch for follow-up 8-K vs peers' clearer risks

BKYI to OTC same ticker post-May 13; potential price dislocation for nimble traders vs Nasdaq peers

Hearing Panel decision post-May 13 appeal; low-probability reinstatement could spike if successful

Annual meeting 'as soon as practicable' post-plan; governance fix could stabilize vs Beauty's vagueness

Ties to 2025 10-K risks; alpha from shorting if parallels BKYI's late filing pattern

3/3 high materiality delisting risks; portfolio alpha via exiting small-cap Nasdaq exposures pre-suspensions

3/3 filings flag compliance failures (governance, price, filings); clustered May 6 notices imply enforcement wave, pressuring liquidity

BKYI explicit shift post-May 13; 1/3 immediate suspension vs others' plans highlights progression risk, value erosion avg high materiality 9.7/10

2/3 late/delayed processes (10-K, meeting); absent period data suggests QoQ operational decline, no insider conviction signals

All cite compliance intent/plans but with 'no assurance' (BKYI) or 'material differences' (SKIN); mixed remediation outlook across consumer/tech

Avg 9.7/10 rating; no capital allocation trends (dividends/buybacks) to offset, amplifying downside vs compliant peers

Halt at open May 13, 2026; monitor OTC transition and volume drop

Submit to Nasdaq Hearings Panel by May 13, 2026; track decision timeline for reinstatement odds [May 13]

Submit plan within 45 days of May 6 (~June 20, 2026); Nasdaq acceptance for 180-day extension [June 20]

Hold 'as soon as practicable' post-plan; gauge governance fix progress [Post-June 20]

Unspecified deficiency details; watch for remediation timeline or further 8-K [Ongoing post-May 12]

Potential additional notices/hearings; monitor for peer suspensions in small-cap space [May-June 2026]

Post-delisting via Form 25-NSE; track BKYI ticker liquidity and spreads [Post-May 13]